Tandem Diabetes Care (NSDQ:TNDM) increased its full-year sales guidance, citing strong U.S. sales in the third quarter and the launch of its t:slim X2 insulin pump in international markets.
The company increased its 2018 sales guidance from $140 million – $148 million to $150 million – $158 million. If Tandem posts sales within its newly-revised range, annual revenue would be up 39% – 47% compared to 2017.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem lifts full-year sales guidance appeared first on MassDevice.